Pediatricians accounted for increasing proportion of prescriptions dispensed, with 991 percent increase over six years
THURSDAY, Sept. 12, 2024 (HealthDay News) — From 2017 to 2022, there was an increase in naloxone prescribing among adolescents, with pediatricians accounting for an increasing proportion of prescriptions dispensed, according to a study published online Sept. 12 in Pediatrics.
Andrew Terranella, M.D., M.P.H., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues used data from the IQVIA National Prescription Audit Patient Insights, representing 93 percent of all prescriptions from all payers in the United States. Naloxone dispensing trends were described among youths aged 10 to 19 years over time.
The researchers found that 59,077 prescriptions for naloxone were dispensed to youths aged 10 to 19 years from 2017 to 2022. There was a 669 percent increase in dispensing rates, from 6.6 to 50.9 prescriptions per 100,000 adolescents; increases were seen each year. There was variation in spending by specialty and sex. An increasing proportion of prescriptions dispensed were accounted for by pediatricians, with a 991 percent increase over six years. Commercial insurance paid for 74 percent of prescriptions. Low to no cost sharing was seen for most prescriptions, but 20 and 6 percent had out-of-pocket costs exceeding $25 and $75, respectively.
“Naloxone dispensing to youth remains low but has increased markedly from 2017 to 2022,” the authors write. “Pediatricians and other youth-serving clinicians can play an important role in expanding access to naloxone and harm reduction information by prescribing naloxone to all youth who are at risk for overdose.”
Abstract/Full Text (subscription or payment may be required)
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria
Polypharmacy of Prescription Medications Increased for U.S. Older Adults
Low Hydroxychloroquine Intake, Blood Levels Linked to ASCVD Risk in Lupus